290 related articles for article (PubMed ID: 17599035)
1. Meta-analysis technique confirms the effectiveness of anti-TNF-alpha in the management of active ulcerative colitis when administered in combination with corticosteroids.
Rahimi R; Nikfar S; Abdollahi M
Med Sci Monit; 2007 Jul; 13(7):PI13-8. PubMed ID: 17599035
[TBL] [Abstract][Full Text] [Related]
2. A review of infliximab use in ulcerative colitis.
Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis.
Su C; Salzberg BA; Lewis JD; Deren JJ; Kornbluth A; Katzka DA; Stein RB; Adler DR; Lichtenstein GR
Am J Gastroenterol; 2002 Oct; 97(10):2577-84. PubMed ID: 12385442
[TBL] [Abstract][Full Text] [Related]
4. TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis.
Olsen T; Goll R; Cui G; Christiansen I; Florholmen J
Cytokine; 2009 May; 46(2):222-7. PubMed ID: 19286392
[TBL] [Abstract][Full Text] [Related]
5. Anti-TNF-A therapy about infliximab and adalimamab for the effectiveness in ulcerative colitis compared with conventional therapy: a meta-analysis.
Zhou Z; Dai C; Liu WX
Hepatogastroenterology; 2015; 62(138):309-18. PubMed ID: 25916055
[TBL] [Abstract][Full Text] [Related]
6. Infliximab as a rescue therapy for hospitalized patients with severe ulcerative colitis refractory to systemic corticosteroids.
Yamamoto-Furusho JK; Uzcanga LF
Dig Surg; 2008; 25(5):383-6. PubMed ID: 19005257
[TBL] [Abstract][Full Text] [Related]
7. Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy.
Subramaniam K; Richardson A; Dodd J; Platten J; Shadbolt B; Pavli P
Intern Med J; 2014 May; 44(5):464-70. PubMed ID: 24612209
[TBL] [Abstract][Full Text] [Related]
8. Infliximab in the treatment of steroid-dependent ulcerative colitis.
Armuzzi A; De Pascalis B; Lupascu A; Fedeli P; Leo D; Mentella MC; Vincenti F; Melina D; Gasbarrini G; Pola P; Gasbarrini A
Eur Rev Med Pharmacol Sci; 2004; 8(5):231-3. PubMed ID: 15638236
[TBL] [Abstract][Full Text] [Related]
9. Infliximab in ulcerative colitis.
Aberra FN; Lichtenstein GR
Gastroenterol Clin North Am; 2006 Dec; 35(4):821-36. PubMed ID: 17129815
[TBL] [Abstract][Full Text] [Related]
10. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis.
Lawson MM; Thomas AG; Akobeng AK
Cochrane Database Syst Rev; 2006 Jul; (3):CD005112. PubMed ID: 16856078
[TBL] [Abstract][Full Text] [Related]
11. [Infliximab in moderate to severe steroid-dependent or steroid-refractory ulcerative colitis].
Mocciaro F; Orlando A; Scimeca D; Cottone M
Recenti Prog Med; 2007 Nov; 98(11):560-4. PubMed ID: 18044405
[TBL] [Abstract][Full Text] [Related]
12. Infliximab for ulcerative colitis in children and adolescents.
McGinnis JK; Murray KF
J Clin Gastroenterol; 2008 Sep; 42(8):875-9. PubMed ID: 18645529
[TBL] [Abstract][Full Text] [Related]
13. Open-label infliximab therapy in ulcerative colitis: a multicenter survey of results and predictors of response.
Gonzalez-Lama Y; Fernandez-Blanco I; Lopez-SanRoman A; Taxonera C; Casis B; Tabernero S; Bermejo F; Martinez-Silva F; Mendoza JL; Martinez-Montiel P; Carneros JA; Sanchez F; Maté J; Gisbert JP;
Hepatogastroenterology; 2008; 55(86-87):1609-14. PubMed ID: 19102352
[TBL] [Abstract][Full Text] [Related]
14. Meta-analysis: pre-operative infliximab treatment and short-term post-operative complications in patients with ulcerative colitis.
Yang Z; Wu Q; Wu K; Fan D
Aliment Pharmacol Ther; 2010 Feb; 31(4):486-92. PubMed ID: 19925496
[TBL] [Abstract][Full Text] [Related]
15. Infliximab in the treatment of severe ulcerative colitis: a follow-up study.
Kohn A; Prantera C; Pera A; Cosintino R; Sostegni R; Daperno M
Eur Rev Med Pharmacol Sci; 2004; 8(5):235-7. PubMed ID: 15638237
[TBL] [Abstract][Full Text] [Related]
16. Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort.
Gies N; Kroeker KI; Wong K; Fedorak RN
Aliment Pharmacol Ther; 2010 Aug; 32(4):522-8. PubMed ID: 20500733
[TBL] [Abstract][Full Text] [Related]
17. Colectomy rate in acute severe ulcerative colitis in the infliximab era.
Aratari A; Papi C; Clemente V; Moretti A; Luchetti R; Koch M; Capurso L; Caprilli R
Dig Liver Dis; 2008 Oct; 40(10):821-6. PubMed ID: 18472316
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumour necrosis factor therapy for ulcerative colitis: evidence to date.
Thukral C; Cheifetz A; Peppercorn MA
Drugs; 2006; 66(16):2059-65. PubMed ID: 17112300
[TBL] [Abstract][Full Text] [Related]
19. [Anti-TNF-alpha antibody treatment of patients with active ulcerative colitis].
Ainsworth MA; Brynskov J
Ugeskr Laeger; 2007 Feb; 169(9):789-91. PubMed ID: 17355841
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Hibi T; Rutgeerts P;
Gastroenterology; 2014 Jan; 146(1):85-95; quiz e14-5. PubMed ID: 23735746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
